🇺🇸 FDA

Company profile · Sponsor

Hutchmed

Hutchmed Europe B.V.

EDB6DAB · EMA pharma EU
Pipeline
4
Drugs
0
Patents
0

Quick answer

Hutchmed (EDB6DAB) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EDB6DAB
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (4)

Search pipeline →

  1. A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations

    Hutchmed

    - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

    phase 1 other active

    1 trial

  2. A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

    Hutchmed

    - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

    phase 1 other active

    1 trial

  3. A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma

    Hutchmed

    Lymphoma

    phase 1 other active

    1 trial

  4. Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

    Hutchmed

    Primary immune thrombocytopenia (ITP)

    phase 1 other active

    1 trial

Frequently asked questions

What is Hutchmed?

Hutchmed (EDB6DAB) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Hutchmed sponsor?

We track 4 ClinicalTrials.gov-linked programs for Hutchmed, including A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Hutchmed company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.